| 方 祯,卜文静,李伟良,王 霞,许尤琪.康莱特注射液联合信迪利单抗+贝伐珠单抗治疗肝癌患者的效果
及对肝功能、生存质量的影响[J].,2024,(23):4532-4534 |
| 康莱特注射液联合信迪利单抗+贝伐珠单抗治疗肝癌患者的效果
及对肝功能、生存质量的影响 |
| Effect of Conlaite Injection Combined with Sindilizumaband Bevacizumab in the Treatment of Patients with Liver Cancerand Its Influence on Liver Function and Quality of Life |
| 投稿时间：2024-06-12 修订日期：2024-07-10 |
| DOI：10.13241/j.cnki.pmb.2024.23.036 |
| 中文关键词: 康莱特注射液 信迪利单抗 贝伐珠单抗 肝癌 肝功能 |
| 英文关键词: Kanglaite injection Sindilimab Bevacizumab Liver cancer Liver function |
| 基金项目:江苏省卫生健康委科研项目（ZD20211031）；南京中医药大学第二附属医院院级名老中医专家学术经验继承项目
（省二中教育【2023】1号）；南京中医药大学第二附属医院院内科研基金（SEZ202112） |
|
| 摘要点击次数: 18 |
| 全文下载次数: 8 |
| 中文摘要: |
| 摘要 目的：探究康莱特注射液联合信迪利单抗+贝伐珠单抗治疗肝癌患者的效果及对肝功能、生存质量的影响。方法：筛选2021.2至2024.2入院诊治的肝癌患者共90例，分为对照组(信迪利单抗+贝伐珠单抗治疗)和观察组(康莱特注射液联合信迪利单抗+贝伐珠单抗治疗)，各45例。对比两组相关指标。结果：观察组治疗总有效率高于对照组(P＜0.05)。治疗后观察组TBil、DBil、AST、ALT指标水平均低于对照组(P＜0.05)。治疗后，两组CD4+、NK指标水平升高，CD8+指标水平降低，观察组较对照组比较有差异(P＜0.05)。治疗后观察组CEA、AFP、CA199指标水平均低于对照组(P＜0.05)。治疗后观察组KPS评分高于对照组(P＜0.05)。结论：康莱特注射液联合信迪利单抗+贝伐珠单抗治疗肝癌患者可提高治疗总有效率，改善肝功能，提升免疫功能，降低肿瘤标志物水平，提高生活质量。 |
| 英文摘要: |
| ABSTRACT Objective: To explore the efficacy of Kanglaite injection combined with Sindilizumab and bevacizumab in the treatment of liver cancer patients and the influence on liver function and quality of life. Methods: A total of 90 patients with liver cancer who were hospitalized from 2021.2 to 2024.2 were selected and divided into control group (sintilimab+bevacizumab treatment) and observation group (Conlett injection combined sintilimab+bevacizumab treatment), 45 cases in each group. Compare the two groups of relevant indicators. Results: The total effective rate of observation group was higher than that of control group (P<0.05). After treatment, the levels of TBil, DBil, AST and AST in the observation group were lower than those in the control group (P<0.05). After treatment, two groups of CD4+ and NK index levels, CD8+ index levels, there are differences between the observation group than the control group comparison (P<0.05). After treatment, the levels of CEA, AFP and CA199 in observation group were lower than those in control group (P<0.05). After treatment, the KPS score of observation group was higher than that of control group (P<0.05). Conclusion: Kanglaite injection combined with sindillizumab and bevacizumab in the treatment of liver cancer patients can increase the total response rate, improve liver function, enhance immune function, reduce the level of tumor markers, and improve the quality of life. |
|
查看全文
查看/发表评论 下载PDF阅读器 |
| 关闭 |
